A61P 35 - Antineoplastic agents

Patents for A61P 35 - Antineoplastic agents (221,099)
08/2011
08/18/2011	US20110201540 Glycosylation of Molecules
08/18/2011	US20110201496 Substituted 5-Hetaryl-4-Aminopyrimidines
08/18/2011	US20110201092 Listeria attenuated for entry into non-phagocytic cells, vaccines comprising the listeria, and methods of use thereof
08/18/2011	US20110201029 Il-13 receptor antibodies
08/18/2011	US20110200695 Gel composition for filling a breast milk duct prior to surgical excision of the duct or other breast tissue
08/18/2011	US20110200694 Promotors of Ceramide's Generation
08/18/2011	US20110200692 Use of a cinnamon bark extract for treating amyloid-associated diseases
08/18/2011	US20110200689 Methods for treating glioblastoma with herbal compositions
08/18/2011	US20110200686 Compositions of modulators of the wnt/b-catenin pathway and an n-cinnamyl-n'benzhydryl piperazine and their use in treating neoplastic conditions including malignant melanoma
08/18/2011	US20110200677 Prostate specific membrane antigen (psma) targeted nanoparticles for therapy of prostate cancer
08/18/2011	US20110200673 Oxidized heparin fractions and their use in inhibiting angiogenesis
08/18/2011	US20110200665 Novel Thermosensitive Liposomes Containing Therapeutic Agents
08/18/2011	US20110200629 Tumor antigen peptide and use thereof
08/18/2011	US20110200627 Anti-cd147 antibodies, methods and uses
08/18/2011	US20110200626 Iqgap3 epitope peptides and vaccines containing the same
08/18/2011	US20110200625 Pharmaceutical composition
08/18/2011	US20110200624 Novel peptides for use in transfection
08/18/2011	US20110200622 Polypeptide specifically binding to vascular endothelial growth factor, fusion protein including polypeptide, and methods therefor
08/18/2011	US20110200621 Compositions and methods for treating cancer
08/18/2011	US20110200620 B7-h1 and methods of diagnosis, prognosis, and treatment of cancer
08/18/2011	US20110200619 Pharmaceutical compounds as cytotoxic agents and uses thereof
08/18/2011	US20110200608 Fully human antibodies to high molecular weight-melanoma associated antigen and uses thereof
08/18/2011	US20110200607 Binding Proteins Specific for Insulin-Like Growth Factors and uses Thereof
08/18/2011	US20110200606 Antibodies that Bind to Lysyl Oxidase-Like 2 (LOXL2) and Methods of Use Therefor
08/18/2011	US20110200602 Antibodies to egfl7 and methods for their use
08/18/2011	US20110200599 Sustained drug delivery system
08/18/2011	US20110200598 Combination therapy of a type ii anti-cd20 antibody with a proteasome inhibitor
08/18/2011	US20110200597 Signal pathway alterations and drug target elevations in primary metachronous metastatic colorectal cancer compared to non-metastatic disease
08/18/2011	US20110200596 Monovalent antibody fragments useful as therapeutics
08/18/2011	US20110200595 TREATMENT WITH A HUMANIZED IgG CLASS ANTI EGFR ANTIBODY AND AN ANTIBODY AGAINST INSULIN LIKE GROWTH FACTOR 1 RECEPTOR
08/18/2011	US20110200589 Deconvolution method
08/18/2011	US20110200587 Aminothiazolones as estrogen related receptor-alpha modulators
08/18/2011	US20110200586 Aminothiazolones as estrogen related receptor-alpha modulators
08/18/2011	US20110200582 Lipids, lipid compositions, and methods of using them
08/18/2011	US20110200581 Pharmaceutical compositions
08/18/2011	US20110200579 Novel gene disruptions, compositions and methods relating thereto
08/18/2011	US20110200576 Engineered enzymes with methionine-gamma-lyase enzymes and pharmacological preparations thereof
08/18/2011	US20110200565 Virus clearance of neoplastic cells from mixed cellular compositions
08/18/2011	US20110200562 Chimeric Cytokine of IL-7 and Beta Chain of HGF and Methods of Use
08/18/2011	US20110200556 Chemoprevention of head and neck squamous cell carcinomas
08/18/2011	US20110200552 Cytokine design
08/18/2011	US20110200550 Multi-Arm Polymeric Alkanoate Conjugates
08/18/2011	US20110200542 Skin cancer prevention method and product
08/18/2011	US20110200541 Recombinant preparation of bromelain inhibitors and bromelain inhibitor precursor
08/18/2011	US20110200530 Targeting construct comprising anti-polymer antibody and contrast/therapeutic agents binding to the same
08/18/2011	US20110200527 Peptide Ligand Directed Drug Delivery
08/18/2011	US20110200526 System for Concurrent Delivery of Thermobrachytherapy in the Treatment of Cancers
08/18/2011	US20110200525 Vhh antibody fragments for use in the detection and treatment of cancer
08/18/2011	US20110200524 Vector for use in medicine
08/18/2011	DE102010008643A1 New 5'-biphenyl substituted cyclic ketoenol compounds are acetyl-coenzyme A carboxylase 1 inhibitors, useful for treating cancer e.g. breast cancer, pancreatic cancer, renal cell carcinoma, hepatocellular carcinoma and skin tumor
08/18/2011	DE102010008642A1 New 5'-biphenyl substituted cyclic ketoenol compounds are acetyl-coenzyme A carboxylase 1 inhibitors, useful for treating cancer e.g. breast cancer, pancreatic cancer, renal cell carcinoma, hepatocellular carcinoma and skin tumors
08/18/2011	CA2827015A1 Hybrid molecule having mixed retinoic acid receptor agonism and histone deacetylase inhibitory properties
08/18/2011	CA2789989A1 Process for the preparation of alpha form of imatinib mesylate
08/18/2011	CA2789847A1 Kinase modulators for the treatment of cancer
08/18/2011	CA2789551A1 Cyclic keto-enols for therapy
08/18/2011	CA2789517A1 Use of the lactosylceramide synthase isoform b1,4galt-v as a biomarker for cancer
08/18/2011	CA2789310A1 Radioactive metal-labeled anti-cadherin antibody
08/18/2011	CA2789276A1 New signaling molecule involved in ultraviolet damage to skin
08/18/2011	CA2789229A1 Tryptophan hydroxylase inhibitors for the treatment of metastatic bone disease
08/18/2011	CA2788533A1 Salt of fused heterocyclic derivative and crystal thereof
08/18/2011	CA2788459A1 Methods of synthesizing and isolating n-(bromoacetyl)-3,3-dinitroazetidine and a composition including the same
08/18/2011	CA2788400A1 Antibodies against cxcr4
08/18/2011	CA2788284A1 Alpha-methyl-tryptophan as an inhibitor of indoleamine dioxygenase
08/18/2011	CA2788236A1 Substituted pyrrolidine-2-carboxamides
08/18/2011	CA2787881A1 Salts and polymorphs of 8-fluoro-2-{4-[(methylamino}methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one
08/18/2011	CA2787823A1 Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
08/18/2011	CA2786973A1 6-amino-2-{ [ (1s)-1-methylbutyl] oxy}-9-[5-(1-piperidinyl)-7,9-dihydro-8h-purin-8-one maleate
08/18/2011	CA2780922A1 7-aminofuropyridine derivatives
08/17/2011	EP2357582A1 Methods and devices for identifying patterns in biological systems
08/17/2011	EP2357249A1 Macrolide compounds
08/17/2011	EP2357202A1 Targeted binding agents directed to Upar and uses thereof
08/17/2011	EP2357200A1 Human antibodies that bind human TNFalpha
08/17/2011	EP2357195A1 Growth factor complexes and modulation of cell migration and growth
08/17/2011	EP2357194A1 Growth factor complexes and modulation of cell migration and growth
08/17/2011	EP2357193A1 Human GIL-19/AE289 proteins and polynucleotides encoding same
08/17/2011	EP2357182A1 Inhibitors of tyrosine kinases
08/17/2011	EP2357181A1 2,4-Diaminopyrimidines as inhibitors of cell cycle kinases
08/17/2011	EP2357176A1 Amidoacridine derivatives useful as selective inhibitors of ubiquitin specific protease 7
08/17/2011	EP2357166A1 Auto magnetic metal salen complex compound
08/17/2011	EP2357009A1 Duramycin peptide binding to anionic phospholipids and aminophospholipids conjugates and their use in treating viral infections
08/17/2011	EP2357008A1 Albumin fusion proteins
08/17/2011	EP2357006A2 Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
08/17/2011	EP2357005A1 Co-administration of CG250 and IL-2 or IFN-alpha for treating cancer such as renal cell carcinomas
08/17/2011	EP2357004A1 NRG-2 nucleic acid molecules, polypeptides and diagnostic and therapeutical methods
08/17/2011	EP2357003A2 Anticancer composition comprising antitumor agent and substance having inhibitory effects on l1cam activity and expression
08/17/2011	EP2357002A1 Nucleic acid molecules and polypeptides for immune modulation
08/17/2011	EP2356999A1 Compositions to elicit, enhance and sustain immune responses against MHC class I-restricted epitopes, for prophylactic or therapeutic purposes
08/17/2011	EP2356995A2 Process of preparation of formulations of the peptide Angiotensin-(1-7) and its analogues, agonists and antagonists using cyclodextrins, liposomes and biodegradable polymers and/or mixtures and products thereof
08/17/2011	EP2356994A2 Identification of actinobacillus actinomycetemcomitans antigens for use in the diagnosis, treatment, and monitoring of periodontal diseases
08/17/2011	EP2356234A2 Dosage of oligonucleotides suitable for the treatment of tumors
08/17/2011	EP2356230A1 Cancer related gene, lgn/gpsm2
08/17/2011	EP2356152A1 Anti-tgf-beta receptor ii antibodies
08/17/2011	EP2356128A1 Oligosaccharide compounds for use in mobilising stem cells
08/17/2011	EP2356122A1 Protein kinase inhibitors
08/17/2011	EP2356120A1 Imidazo[1,5]naphthyridine compounds, their pharmaceutical use and compositions
08/17/2011	EP2356117A1 Pyrazolopyridine pi3k inhibitor compounds and methods of use
08/17/2011	EP2356116A1 Substituted pyrroloý2,3-b¨-pyridines and-pyrazines
08/17/2011	EP2356114A1 Aminoalkyl-substituted compounds as hif inhibitors
08/17/2011	EP2356113A1 Heterocyclically substituted aryl compounds as hif inhibitors
08/17/2011	EP2356112A1 Heteroaromatic compounds for use as hif inhibitors

1 ... 475 476 477 478 479 480 481 482 483 484 485 486 487 488 489 490 491 492 493 494 495 ... 2211